Predictive Oncology Inc. Q4 FY2023 earnings call

• Over the past 12 months, the company has restructured, repositioned, and implemented a new strategic vision for predictive oncology, identifying unutilized assets and bolstering intellectual property. - Worked with CRH to evaluate preclinical glutaminase inhibitor drug compounds, identifying responsive patient subpopulations across four tumor types. - Completed a multi-year retrospective study with UPMC Magee-Women’s Hospital on ovarian cancer, developing predictive models and exploring clinical applications. - Made progress with Cvergenx on precision radiation therapy and drug discovery, submitted a proposal to the RK Mellon Foundation, and had a collaboration with FluGen awarded a Phase 2B grant. - Engaged in co-marketing plans with Fuji for endotoxin detection and treatment technologies, and had significant conference presence in early 2024.

In 2023, the company's revenue was $1.8 million, compared to $1.5 million in 2022. The Eagan operating segment contributed $1.135 million in 2023 and $1.064 million in 2022. The Pittsburgh operating segment contributed $493,000 in 2023 and $359,000 in 2022. Operating expenses decreased by $142,000 to $3.7 million in 2023 from $3.8 million in 2022, with decreases in research and development expenses offset by higher cloud computing expenses. Net cash used in operating activities was $13.2 million in 2023 compared to $12.4 million in 2022, net cash used in investing activities was $302,000 in 2023 compared to $476,000 in 2022, and net cash provided by financing activities was $149,000 in 2023 compared to $67,000 in 2022.

Forward-looking statements are subject to substantial risks and uncertainties, including factors discussed in the SEC filings' Risk Factors section, where actual future performance may materially differ from forward-looking statements.

Q: None A: None